Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models

Michael Dietrich, PhD,* Christina Hecker, MSc,* Elodie Martin, PhD, Dominique Langui, PhD, Michael Gliem, MD, Bruno Stankoff, MD, PhD, PU-PH, Catherine Lubetzki, MD, PhD, PU-PH, Joel Gruchot, MSc, Peter Göttle, PhD, Andrea Issberner, Milad Nasiri, MD, Pamela Rameiser, Christian Beerli, Sarah Tisserand, MSc, Nicolau Beckmann, PhD, Derya Shimshek, PhD, Patrick Petzsch, PhD, David Akbar, MSc, Bodo Levkau, Prof., Holger Stark, Prof., Karl Köhler, Prof., Hans-Peter Hartung, Prof., Patrick Kury, Prof., Sven Günther Meuth, Prof., Marc Bigaud, PhD, Bernhard Zalc, Prof.,† and Philipp Albrecht, Prof.†

Neurol Neuroimmunol Neuroinflamm 2022;9:e1161. doi:10.1212/NXI.0000000000001161

Abstract

Background and Objectives
Siponimod is an oral, selective sphingosine-1-phosphate receptor-1/5 modulator approved for treatment of multiple sclerosis.

Methods
Mouse MRI was used to investigate remyelination in the cuprizone model. We then used a conditional demyelination Xenopus laevis model to assess the dose-response of siponimod on remyelination. In experimental autoimmune encephalomyelitis–optic neuritis (EAEON) in C57Bl/6J mice, we monitored the retinal thickness and the visual acuity using optical coherence tomography and optomotor response. Optic nerve inflammatory infiltrates, demyelination, and microglial and oligodendroglial differentiation were assessed by immunohistochemistry, quantitative real-time PCR, and bulk RNA sequencing.

Results
An increased remyelination was observed in the cuprizone model. Siponimod treatment of demyelinated tadpoles improved remyelination in comparison to control in a bell-shaped dose-response curve. Siponimod in the EAEON model attenuated the clinical score, reduced the retinal degeneration, and improved the visual function after prophylactic and therapeutic treatment, also in a bell-shaped manner. Inflammatory infiltrates and demyelination of the optic nerve were reduced, the latter even after therapeutic treatment, which also shifted microglial differentiation to a promyelinating phenotype.

Discussion
These results confirm the immunomodulatory effects of siponimod and suggest additional regenerative and promyelinating effects, which follow the dynamics of a bell-shaped curve with high being less efficient than low concentrations.

*Equally contributing first authors.
†Equally contributing senior authors.

From the Department of Neurology (M.D., C.H., M.G., J.G., P.G., A.I., M.N., H.-P.H., P.K., S.G.M.), Heinrich Heine University Düsseldorf, Medical Faculty (P.A.), Düsseldorf, Germany; Sorbonne Université (E.M., D.L., B.S., C.L., D.A., B.Z.), Inserm, CNRS, Institut du Cerveau, Pitie-Salkétrie Hospital; AP-HP (B.S.), Saint-Antoine Hospital; AP-HP (C.L.), Pitie-Salkétrie Hospital, Paris, France; Novartis Institutes for BioMedical Research (P.R., C.B., S.T., N.B., D.S., M.B.), Basel, Switzerland; Biological and Medical Research Center (BMFZ) (P.P., K.K.), Heinrich Heine University Düsseldorf, Medical Faculty; Institute for Molecular Medicine III (B.L.), University Hospital Düsseldorf and Heinrich Heine University Düsseldorf; Institute of Pharmaceutical and Medicinal Chemistry (H.S.), Heinrich Heine University Düsseldorf, Duesseldorf, Germany; Brain and Mind Center (H.-P.H.), University of Sydney, NSW, Australia; and Medical University of Vienna (H.-P.H.), Vienna, Austria.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Siponimod, a potent and highly selective sphingosine-1-phosphate receptor 1 and 5 (S1P1/5) modulator, is a disease-modifying therapy that significantly reduced disability progression, cognitive decline, and total brain volume loss vs placebo in patients with secondary progressive multiple sclerosis (SPMS), as demonstrated in the phase III EXPAND study. It has beneficial effects in the CNS of experimental autoimmune encephalomyelitis (EAE) mice that are independent of peripheral immune effects, suggesting that in addition to its anti-inflammatory effects, siponimod may be effective in limiting neurodegenerative pathologic processes in SPMS.

Promoting remyelination is another key therapeutic strategy to limit disability progression and represents one of the major therapeutic challenges in MS. Therefore, experimental models to investigate substances promoting remyelination in vivo are of paramount interest. The cuprizone intoxication mouse model is a well-established mechanistic model to study remyelination processes. As oligodendrocyte precursor cells (OPCs) are not affected by cuprizone, they readily proliferate, migrate, differentiate, and integrate again into the circuitry resulting in remyelination after withdrawal. Novel data from a Xenopus laevis demyelination model indicated a remyelinating potential of siponimod. Optic neuritis (ON) presenting with acute inflammatory relapses. Therefore, in this innovative approach investigating the visual pathway of siponimod-treated EAE-associated ON (EAEON) mice, we used longitudinal visual system readouts, revealing yet unknown mechanisms on the shift of the microglial cell population toward a regenerative phenotype.

Methods

Cuprizone Intoxication Model and Measurement of C57Bl/6J Mice

Cuprizone preparation and randomization is described in the eMethods. In brief, female C57Bl/6J mice (8–10 weeks old from Charles River, Germany) received normal diet over 7 weeks (control group) or were fed with cuprizone-loaded pellets (2 g/kg food) for 5 weeks and then switched either to siponimod-loaded pellets (10 mg/kg food) over 2 weeks (cuprizone-siponimod group) or to drug-free pellets (cuprizone/sham group). MRI measurements were performed at weeks 5, 6, and 7 and histology on week 7 with LFB and GST-π as described in the eMethods, links.lww.com/NXI/A706.

Xenopus laevis Demyelination Model

To test the effect of siponimod on remyelination in vivo, we used a conditional demyelination transgenic model, Tg(mbp: GFP-NTR), developed in Xenopus laevis as described before and in the eMethods. Before the quantification of GFP+ cells, we anesthetized the tadpoles of either sex in 0.05% MS-222 (ethyl-3-aminobenzoate methanesulfonate; Sigma-Aldrich) and returned them to standard water conditions for recovery. Tadpoles were euthanized in 0.5% MS-222 before the optic nerve was dissected.

For regeneration experiments, metronidazole (MTZ)-exposed animals (MTZ preparation described in the eMethods) were allowed to recover for 3 days in either normal water (control) or water containing siponimod at increasing concentrations in ambient laboratory lighting (12 hours light/12 hours dark).

Induction of EAEON and Treatment of C57Bl/6J Mice

EAEON was induced in female, 6-week-old C57Bl/6J by 200 μg MOG35-55 (Biotrend, Germany) immunization followed by intraperitoneal injections of 200 ng of pertussis toxin.
(Sigma-Aldrich, Germany) at days 0 and 2 as previously described. Mice were fed with siponimod-loaded pellets at 0.01 or 0.03 g/kg of food, leading to a daily drug intake of approximately 2 and 6 mg/kg bodyweight, respectively (considering a mean daily food intake of 3 g/mouse). Treatment was started at the same day (d0), 14 days (d14), or 30 days (d30) after MOG35-55 immunization. The clinical EAE score was graded daily as described previously.

**OCT and OMR in Mice**

The measurements of retinal layers were performed using a Spectralis HRA + OCT device (Heidelberg Engineering, Germany) with several adaptors for rodents. The analysis and scanning protocols are described elsewhere and in the eMethods, links.lww.com/NXI/A706. Visual function analysis was performed with a testing chamber and OptoMotry software from CerebralMechanics, Canada, as previously described and explained in detail in the eMethods, links.lww.com/NXI/A706.

**Histologic Analysis**

**Wholemount of the Xenopus Optic Nerve and Analysis**

Tadpoles were fixed by immersion in 4% paraformaldehyde for 1 hour at room temperature. Fixed optic nerves were carefully dissected out and processed as described in the eMethods. In brief, oligodendrocytes were stained with anti-GFP (1:1,000, Aves Lab) and microglial cells with Bandeiraea simplicifolia isolectin B4 (Alexa Fluor594-conjugated IB4, 1:1,000, Invitrogen), and images were acquired using the Olympus FV-1200 upright confocal microscope (Obj 20X-zoom 1.6).

**Electron Microscopy of Xenopus Tadpole Optic Nerve**

Xenopus larvae were fixed in a mixture of 2% paraformaldehyde, 2% glutaraldehyde, in 0.1 M cacodylate buffer pH 7.4 and 0.002% calcium chloride overnight at 4°C and processed as described in the eMethods, links.lww.com/NXI/A706. Ultrathin sections were examined on an HT7700 electron microscope (Hitachi) operated at 70 kV. Electron micrographs were taken using the integrated AMT XR41-B camera (2048X2048 pixels).

**Quantification of GFP+ Cells in the Xenopus Optic Nerve**

As described previously, GFP fluorescence was analyzed directly in vivo in Xenopus embryos using an AZ100 Nikon Multizoom Macro-Microscope. From the emergence of the optic nerve, directly after the chiasm, to the retinal end, the total number of GFP+ cells was counted independently by 2 researchers in a double-blinded manner. The counts were compared with control untreated animals of the same developmental stage.

**Wholemounts and Histologic Optic Nerve Analysis of C57Bl/6j EAEON Mice**

After 21, 35, or 90 days of EAEON, mice were killed, and eyes and optic nerves were extracted and processed as described in the eMethods.

**Bulk RNA Sequencing of the Optic Nerve From EAEON Mice**

RNA extraction was performed as previously described. RNA was stored at –80°C until analysis as described in the eMethods, links.lww.com/NXI/A706.

**qPCR Analysis of the Optic Nerve of EAEON C57Bl/6j Mice**

RNA extraction, reverse transcription, and quantitative real-time PCR were performed as previously described using Fam/Dark quencher probes from the Universal Probe Library (Roche, Switzerland) or individually designed Fam/Tamra probes (Eurofins Genomics, Germany). HPRT and GAPDH served as endogenous control genes. Primer sequences can be found in eTable 1, links.lww.com/NXI/A706.

**Statistics**

Statistical analysis was performed using Prism 5 (version 5.00, Graphpad Software, Inc.) and IBM SPSS Statistics (version 20, IBM Corporation, USA). A 2-tailed analysis of variance (ANOVA) with the Dunnett post hoc test was used to compare the area under the curve for the EAE scores and blood siponimod concentration time courses. qPCRs were analyzed using 2-way ANOVA with the Bonferroni post hoc test. Group means were compared by 1-way ANOVA with the Dunnett post hoc test using 1 eye per animal for the histologic investigations. Differences in retinal thickness and visual function were analyzed using generalized estimating equations with an exchangeable correlation matrix to adjust for intrasubject intereye correlations.

MRI data were analyzed using ANOVA with random effects (Systat version 13; Systat Software Inc., San Jose, CA) to take into account the longitudinal structure of the data. A value of $p < 0.05$ was considered significant. For the RNaseq, the statistical analysis is described in the eMethods, links.lww.com/NXI/A706.

**Study Approval**

**C57Bl/6j Mice**

The procedures were performed in accordance with the Animal Research: Reporting of In Vivo Experiments guidelines, approved by the regional authorities (State Agency for Nature, Environment and Consumer Protection; AZ.84-02.04.2016.A137) and conform to the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. Cuprizone studies were approved by the Swiss Cantonal Veterinary Authority of Basel City, Switzerland (license BS-2711).

**Xenopus laevis Tadpoles**

Animal care was in compliance with institutional and national guidelines. All animal experiments conformed to the European Community Council directive (86/609/EEC) as modified (2010/603/UE) and have been approved by the ethical committee of the French Ministry of Higher Education and Research (APA#5842-2016101312021965).
Data Availability
Data not provided in the article because of space limitations may be shared at the request of any qualified investigator for purposes of replicating procedures and results.

Results
Siponimod Promotes Remyelination After Cuprizone Intoxication
We used the cuprizone model of toxic demyelination to study siponimod’s effects on remyelination in vivo. During the 5-week intoxication phase, no particular health issue could be detected in cuprizone-treated vs control mice, and similar longitudinal bodyweight changes vs baseline were observed in the 3 study groups (Figure 1A). Hence, at the start of the treatment, all 3 groups presented similar mean bodyweights (21.9 ± 0.4 g; 21.4 ± 0.4 g; and 22.2 ± 0.3 g).

Over the following 2 weeks, the mice that received drug-free pellets (cuprizone/sham group) showed a slight but significant loss in bodyweight vs controls. This was not observed in mice that received siponimod-loaded pellets (cuprizone/siponimod group) (Figure 1A). In this group, the mean siponimod concentrations measured in blood and brain homogenates were within the expected ranges, that is, 0.41 ± 0.01 μM and 2.7 ± 0.7 nmol/g (equivalent to 2.7 ± 0.7 μM), respectively, confirming the success of the treatment.

As expected, cuprizone-intoxicated mice showed marked demyelination within their CC at week 5, as suggested by significantly decreased magnetization transfer ratio (MTR) in these regions when compared with values in control mice (Figure 1C). On cuprizone washout in weeks 5–7, MTR in mice fed with drug-free pellets increased in the CC (Figure 1C), suggesting spontaneous partial remyelination. This effect was particularly evident when calculating the area under the curve (AUC) (eFigure 1A, links.lww.com/NXI/A706). Five weeks of cuprizone intoxication resulted also in T2-weighted CC signal increases by 53% (Figure 1B). After cuprizone withdrawal at week 5, the T2-weighted signal intensity (T2-WSI) was reduced in the CC at weeks 5–7 (Figure 1D), consistent with spontaneous partial remyelination and reduction of neuroinflammation in these areas.27 Addition of siponimod to food pellets increased...
this reduction of T2-WSI (Figure 1D) with a significant difference to siponimod-free pellet treated mice in the CC. This effect was again particularly evident when analyzing the AUC (eFigure 1B). T2-WSI in the CC of control mice remained unaltered. Both MTR and T2-WSI data of the CC indicate the beneficial effects of siponimod treatment in the cuprizone model. Terminal qIHC for LFB density and oligodendrocyte numbers (GST-\(\pi\)) revealed a degree of myelination in the CC reduced by about half in cuprizone-challenged mice receiving drug-free food pellets vs controls. A trend toward a lower degree of CC demyelination was observed in siponimod-treated mice, with changes in LFB density and oligodendrocyte numbers reduced by about 25–45% vs siponimod-free mice (eFigure 1).

**Siponimod-Driven Activation of S1P1/5 Receptor Promotes Remyelination**

Conditional oligodendrocyte ablation and demyelination followed by spontaneous remyelination was investigated in the Tg(mbp:GFP-NTR) *Xenopus laevis* model, and the dynamics are reported in eAppendix 1 and eFigure 2, links.lww.com/NXI/A706. Demyelination and remyelination were analyzed by counting the number of GFP+ cells per optic nerve in vivo before (D0), at the end of MTZ treatment (D10), and then on day 3 (R3) of the repair period. To assess remyelination potency on stopping MTZ exposure, siponimod was added in the swimming water at nominal doses ranging from 0.1 nM to 1 \(\mu\)M. Under these conditions, siponimod accumulated over time in tadpole tissues in a dose-proportional manner reaching mean levels of 30–60 pmol/g (equivalent to 30–60 nM) at nominal doses \(\leq\) 3 nM, whereas mean tissues exposures equivalent to 0.6, 1.7, and 36 \(\mu\)M were achieved at the nominal dose of 0.03, 0.1, and 1 \(\mu\)M, respectively. Of interest, at all nominal doses tested, similar siponimod levels were measured in brain vs body samples, with a mean brain/body ratio of 0.9 ± 0.3.

Siponimod treatments, at nominal doses from 0.1 to 3 nM, improved remyelination in a dose-dependent manner, with a maximal and significant 2.3 ± 0.2 fold increase vs control observed at the nominal dose of 1 nM (i.e., achieving about 60 nM accumulated in tissues over 3 days). At nominal doses > 3 nM (i.e., > 60 nM in tissues), the promyelination effect of siponimod reduced markedly in a dose-dependent manner, with nearly no trend observed at nominal doses \(\geq\) 30 nM (i.e., 600 nM accumulated in tissues), revealing an unclassical bell-shaped overall dose-response curve for siponimod in this remyelination model (Figure 2A).

In addition to S1P5, siponimod acts also on S1P1, a receptor expressed by microglia. To explore the effect of siponimod...
treatment on microglial cells, transgenic Tg(mbp:GFP-NTR) Xenopus were demyelinated by 10-day exposure to MTZ (10 mM) and then returned to either normal water or water containing siponimod (1 nM) for 3 days. Optic nerves were dissected and doubly labeled with IB4 isolectin and anti-GFP (Figures 2, B and C). In addition to the expected increase (2.04 fold vs ctrl \( p = 0.017 \)) in the number of GFP+ cells, we also observed a 1.81 fold increase (\( p < 0.0001 \)) in the number of IB4-labeled microglial cells (Figure 2C). After 3 days of recovery, microglial cells presented with an elongated morphology, extending their processes along the optic nerve, and we did not notice a change in the morphology of microglia on siponimod treatment (Figure 2B).

To verify that the siponimod-induced increased number of oligodendrocytes (GFP+ cells) translated into increased myelination, optic nerves were dissected and processed for electron microscopy. The number of myelinated axons quantified on semithin sections was nearly doubled (1.97 ± 0.14 fold vs ctrl; \( p = 0.042 \)) (Figure 2C), and there was no noticeable morphologic changes compared with control conditions (Figure 2D).

**Siponimod Reduces the Disability Score and Retinal Degeneration in an EAEON Model**

Before investigating the effects of siponimod on EAEON, we performed a pharmacokinetic study, which demonstrated that treatment by loaded food pellets was superior to supply by drinking water and showed a robust effect on circulating blood cell counts in flow cytometry (eAppendix 1, eFigure 3, and eFigure 4, links.lww.com/NXI/A706). After observing these promising data in the cuprizone and the Xenopus laevis demyelination models, we longitudinally investigated retinal neurodegeneration in MOG33-55 peptide–induced EAEON in C57BL/6j mice over 90 days to test the potential of siponimod to protect from acute inflammatory relapses, as well as chronic degeneration, similar to the progression of SPMS. In this model, prophylactic siponimod treatment acted beneficially on clinical EAE scores with more pronounced effects compared with therapeutic treatment. Siponimod prophylactic diet treatments at 2 and 6 mg/kg BW attenuated the clinical EAE scores by approximately 80% and 95%, respectively. The therapeutic effect was significant with the lower dose (2 mg/kg) at both time points and when started at d14 almost similar to the prophylactic treatment (Figure 3A).
Analyzing the structural changes by OCT, untreated sham control mice showed a nearly constant IRL thickness, whereas MOG peptide–immunized animals presented a prominent loss of IRL thickness until day 90. Prophylactic siponimod therapy at 2 and 6 mg/kg BW reduced the OCT-measured degeneration of the IRL by approximately 50%. Beneficial effects were observed with therapeutic diet treatments starting at day 14, with 2 mg/kg BW being superior over 6 mg/kg BW (p < 0.01), but not at day 30 (Figure 3B). Analyzing the visual acuity, a strong decrease of spatial frequency over 90 days of vehicle-treated MOG EAE mice was revealed. This was significantly prevented by almost all therapeutic interventions, despite the late treatment (d30) with the higher dose (6 mg/kg) of siponimod (Figure 3C). These effects, measured longitudinally in vivo, were well reflected by the investigation of RGC survival 90 days postimmunization (dpi). Prominent RGC loss of untreated EAE animals was diminished by siponimod prophylactic diet, as well as therapeutic treatment with 2 mg/kg, but not 6 mg/kg starting 14 dpi (Figure 3D).

**Siponimod Prevents Inflammation and Demyelination of the Optic Nerve**

To assess the effects of siponimod on immune cell infiltration into the CNS during EAE, we performed histologic analyses of Iba1+ microglia/macrophages and CD3+ T cells in longitudinal optic nerve sections (Figure 4A). A significant

---

**Figure 4 Prophylactic Siponimod Therapy Reduces Immune Cell Infiltration and Prevents Demyelination**

(A) Longitudinal sections of optic nerves of C57Bl/6J mice were stained for Iba1, CD3, and MBP 90 days after myelin oligodendrocyte glycoprotein fragment 35-55 immunization; dotted lines indicate areas of demyelination, scale bar = 50 μm. Quantitative analyses of microglial activation (Iba1, B) by fluorescence intensity measurement, T-cell infiltration (CD3 score, C), and myelin status (MBP score, D). One optic nerve per mouse was included. All graphs represent the pooled mean ± SEM, and gray dots show individual data points (n = 6 animals per group out of 2 independent experiments), with *p < 0.05, **p < 0.01, and ***p < 0.001 by ANOVA with the Dunnett post hoc test compared with myelin oligodendrocyte glycoprotein untreated mice. § Few data points out of axis limits. ANOVA = analysis of variance.
reduction of microglial/macrophage activity as well as T-cell infiltration was observed in the optic nerves of mice after prophylactic (d0) siponimod treatment compared with untreated EAE mice. Interventions at later time points did not diminish the infiltrating Iba1+ cells (Figure 4B). Nevertheless, a therapeutic siponimod treatment at the peak of disease (d14) led to a less severe infiltration of CD3+ lymphocytes compared with MOG EAE vehicle–treated mice. When the mice were fed with siponimod-loaded pellets from 30 days after MOG immunization, the number of immune cells could not be reduced at 2 or 6 mg/kg BW (Figure 4C). To test the capacity of siponimod to prevent from demyelination, we analyzed the myelin status of the optic nerve by performing immunohistologic stainings against the myelin basic protein (MBP) protein. The axonal tissue of MOG-immunized mice presented large areas of demyelination, whereas the optic nerves from untreated sham mice showed a homogeneous myelin structure. The MBP-stained lesions in the optic nerve were significantly reduced after a prophylactic siponimod therapy, showing almost the same uniform pattern as sham control animals. Even late siponimod therapy (d14) showed a beneficial effect at 2 mg/kg BW, whereas a treatment starting at day 30 had no significant effect on the myelin loss during EAEON in C57Bl/6j mice until 90 days after immunization (Figures 4, A and D).

Extended analysis of oligodendrocyte populations revealed that siponimod (d14) improved survival of Olig2+ cells in the optic nerve after 35 dpi compared with untreated MOG EAE mice (Figures 5, A and D). As a marker for OPCs, PDGFRα-
stained cells showed no difference in cell number when we compared untreated and siponimod-treated EAE mice at 2 and 6 mg/kg BW, whereas sham control mice had higher OPC numbers at 21 and 35 dpi (Figures 5, B and D). Similar as after 90 dpi, early demyelination was reduced after siponimod therapy for both doses (Figures 5, C and D). Increased astrocytosis in the optic nerve, analyzed by GFAP staining, was observed in MOG EAE mice after 21 and 35 dpi, whereas no effect of siponimod was observed (eFigure 5, links.lww.com/NXI/A706).

In the retina of the mice, we assessed microglia (Iba1) and astrocyte/Mueller cell (GFAP) appearance also 90 days after MOG immunization. We found an increased number of Iba1+ cells in untreated EAEON animals compared with sham mice, but only observed a significant decrease for microglial numbers at the 2 mg/kg BW siponimod dose (d0) (eFigure 6, links.lww.com/NXI/A706).

**Siponimod Shifts Microglia to a Promyelinating Phenotype**

As siponimod still had beneficial effects on the MBP level even in the therapeutic approach (d14), we expanded the experimental and histologic analysis in the optic nerve, testing genes involved in oligodendrocyte as well as microglial regulation. After siponimod treatment (2 mg/kg BW), we found significant upregulation in the optic nerve mRNA expression level 35 dpi of genes marking OPCs NG2 and PDGFRα, as well as for the markers for resting microglia CD206 and TMEM 119 (eFigure 7, A and B, links.lww.com/NXI/A706), which could, however, not be corroborated on the protein level by histologic examinations. Chitinase-3-like-3 (Chi3l3/Ym1) and arginase-1 (Arg-1) mRNA levels were significantly upregulated 21 and 35 dpi, especially after treatment with 2 mg/kg BW siponimod compared with MOG EAE–untreated mice (eFigure 7, C and D). Both are markers for regeneration-supporting microglia. Similar results were observed in BV2 cells, a microglial cell line, where Ym1 and Arg-1 mRNA levels were upregulated after siponimod treatment (eFigure 8, A and B). In addition, mRNA levels of TNF-α, a cytokine expressed by activated, proinflammatory microglia, were significantly reduced after siponimod therapy compared with untreated EAE mice (eFigure 7E).

The transcriptional regulation was monitored by the histologic examination of the optic nerve, where Ym1 (Figures 6, A and D) and Arg-1 (Figure 6, B and D) were found upregulated 21 and 35 dpi after siponimod treatment with a trend toward a more potent effect of the lower siponimod dose (2 mg/kg BW). TNF-α was significantly upregulated in the optic nerve of EAE animals with a peak at 35 dpi, whereas mice under siponimod therapy showed a significantly lower expression of TNF-α (Figures 6, C and D).

**RNA Sequencing Analysis of the EAEON Optic Nerve Reveals Downregulation of Genes Associated With Inflammation After Siponimod Treatment**

In a completely unbiased approach, we used bulk RNA sequencing of the optic nerve of EAEON animals with and without siponimod treatment at 21 dpi, starting the therapy 14 days after immunization (d14). p Values were adjusted for multiple testing to control the false discovery rate (FDR) (pFDR < 0.05), and fold change (FC) was set to 1.5. In a heat map, showing the differentially expressed genes (DEGs), sham and MOG EAE animals show a fully altered expression profile, whereas the DEGs of MOG- and siponimod-treated mice (2 mg/kg) are more similar (Figure 7A). Comparing sham with MOG EAE animals, an upregulation of 2,109 genes and a downregulation of 623 genes were observed, displayed in a volcano plot (Figure 7B). After the siponimod treatment, we found a downregulation of 129 genes and an upregulation of 1 gene after treatment with 2 mg/kg BW siponimod (Figure 7C) and a downregulation of 106 genes with 6 mg/kg BW siponimod compared with untreated MOG EAE control. The 5 most differentially expressed genes associated with inflammation are summarized in eTable 2, links.lww.com/NXI/A706.

**Discussion**

Although the early disease progression in MS can be effectively prevented or mitigated by immunomodulatory therapy, there is still an unmet need for remyelinating strategies and substances to attenuate or inhibit the degeneration occurring in the later stages. Siponimod has recently demonstrated efficacy in SPMS.

As a first step, the remyelinating potential of siponimod after toxic demyelination by cuprizone was investigated by MRI of the corpus callosum. MTR and T2-WSI measurements at 1 week after cuprizone withdrawal demonstrated significant beneficial effects of siponimod treatment on CC integrity. Other studies with the more unspecific S1P1 receptor modulator fingolimod reported a downregulation of S1PR1 brain levels, and fingolimod-treated mice presented more oligodendrocytes in the secondary motor cortex after 3 weeks of remyelination. However, no differences in remyelination or axonal damage were observed compared with placebo. In a novel MS model, a combination of EAE and cuprizone intoxication, siponimod mitigated the extent of demyelination.

To further assess the remyelinating potential of siponimod, we used an inducible experimental model developed in *Xenopus laevis*. After demyelination of the *Xenopus* tadpoles over 10 days, spontaneous remyelination occurred. However, remyelination was significantly accelerated by siponimod in a bell-shaped dose-response curve. We had previously shown that in both the mouse and *Xenopus* brain, S1PR5 is only expressed by oligodendrocytes and that the remyelinating potency of siponimod is lost on deletion of S1PR5. It is therefore likely that the mechanism of action of siponimod-induced remyelination is by activating the myelination program of oligodendrocyte through activation of S1PR5. In addition, as S1P1 is also expressed on microglia, a cell...
population required during spontaneous remyelination, we also investigated their regulation after siponimod treatment. An increased number of IB4+ microglia were observed presenting an elongated morphology 3 days after recovery. In line with this hypothesis, recent observations suggest that in contrast to the S1P1 receptor, the S1P5 receptor is not subject to agonist-induced downmodulation and that siponimod should be considered as a true S1P5 agonist. In this case, a phenomenon such as S1P5 desensitization at supramaximal stimulation could be suspected to explain the bell-shaped curve for the promyelination effect of siponimod.

After these promising results, we then moved to mouse EAE models to investigate the effects in a more disease specific model with translational potential. Siponimod crosses the blood-brain barrier and targets different S1P receptor subtypes, associated with T-cell migration into the CNS, astrogliosis, repair mechanisms via modulation of S1PR5 on oligodendrocytes, and cell survival. Hence, the EAEON model in mice appears as a perfectly suited mechanistic tool to assess the impact of siponimod on all these central effects. In this model, a significant attenuation of the clinical EAE score with 2 and 6 mg/kg BW was observed, when the therapy was
initiated at the day of immunization, in line with previous approaches, using various EAE models in mice and rats. To explore effects of siponimod beyond its immunomodulatory capacity, we not only used different dosing paradigms but also started the siponimod diet at prophylactic (d0) and early or late therapeutic (d14/d30) time points. Other studies addressing similar issues varied only one of these parameters and started treatment no later than 8 days after EAE immunization. A significant beneficial effect on the EAE score was observed when treatment was started at days 14 and 30 after MOG immunization, but surprisingly only with the lower concentration (2 mg/kg BW), indicating a bell-shaped dose-effect curve. We already identified the same dose dependency in a rat MOG28–152–induced EAE in C57Bl/6j mice, where the same dosing (10 mg/kg food or 2 mg/kg BW) led to the most effective reduction of the EAE score of 72.5%, with robust dose-proportional CNS penetration and distribution for siponimod. As preclinical study designs with readouts directly transferable to clinical trials are of increasing interest and other preclinical studies on siponimod’s central effects lack of these techniques, we included visual system measurements to evaluate the results. The IRL, consisting of the RNFL, GCL and IPL contains the axons of the optic nerve, ganglion cells and their dendritic arbor, and is the ideal structure to study neuroprotection and retinal degeneration in MS, as well as in preclinical EAEON studies. As functional readout, the OMR is a suitable measure for the visual acuity in rodents. Although IRL degeneration was attenuated by a prophylactic and a therapeutic 2 mg/kg BW treatment starting 14 dpi, the visual function was even preserved by a therapeutic regimen starting at 30 dpi. This observation was
The reduced number of circulating T cells led to a decreased infiltration of CD3+ cells into the optic nerve, if the intervention was started not later than d14. A therapy at d30 still reduced the circulating T cells by a significant level, but the infiltration into the optic nerve, mainly occurring around days 11–14 at the peak of the EAEON,\(^6^{,7}\) could not be prevented. Antidemyelinating effects, also observed by other researchers in mouse organotypic slice cultures,\(^3^6\) were detected after prophylactic siponimod treatment at both doses and interestingly also after therapeutic treatment with 2 mg/kg BW. As S1P receptors, with the exception of S1P5, are also expressed on microglial cells,\(^3^2\) we expected a reduced number of Iba1-positive cells in the optic nerve after siponimod treatment. However, this effect was only observed after prophylactic therapy, which can be explained by the fact that microgliosis is already present as early as 7 dpi in EAEON.\(^8^{,1}1\) We therefore extended the histologic investigations on genes associated with oligodendrocyte and microglial regulation. We found no transcriptional regulation of genes regulating oligodendrocyte maturation and myelination at the early time points of 21 and 35 dpi. On the other hand, histologic stainings of the optic nerve revealed an improved Olig2+ cell survival at 35 dpi and a less pronounced demyelination at 21 and 35 dpi, measured by the MBP score, similar as at the end point of 90 dpi. Together with the result that no regulation of PDGFRα positive cells by siponimod was found, this indicates an effect of the drug on mature oligodendrocytes rather than on OPCs. Furthermore, we observed significant upregulation of the microglial regenerative markers Ym1 and Arg-1 and a downregulation of the proinflammatory cytokine TNF-α on a transcriptional and translational level at 21 and 35 dpi after siponimod therapy in the optic nerve. In mice, Ym1 is highly expressed in inflammatory brain lesions during EAE and has been demonstrated to induce oligodendrogeneisis.\(^4^{,6}^{,4}6\) Thus, it seems reasonable to assume that the observed beneficial effects of siponimod on the myelin status, observed at 90 dpi may, at least in part, be resulting from its effects on microglial cells, shifting them to a promyelinating phenotype. This is in line with the assumption that the beneficial effects of siponimod go beyond lymphocyte trafficking and rely on its interactions with other cells of the CNS, like astrocytes and neurons, as the drug crosses the blood-brain barrier and S1P receptors are expressed on almost all CNS cell types.\(^4^{,7}\)

In addition to the targeted investigations of oligodendroglial and microglial genes and proteins, we also applied an unbiased approach, analyzing the transcriptome of the optic nerve by bulk RNAseq. It was striking that 129 and 106 genes were downregulated, whereas only 1 and no gene were upregulated after 2 and 6 mg/kg BW siponimod treatment in EAEON, respectively. Significantly downregulated genes potentially altering the disease progression were associated with inflammation. We decided to perform a bulk RNAseq of the whole optic nerve to receive a cell-unspecific, unbiased overview on DEGs after siponimod treatment of EAEON mice. However, a more targeted approach sequencing single cells, such as oligodendrocytes, microglia, or astrocytes, might have led to more homogeneous and conclusive results. As we focused our EAEON study on in vivo readouts of the visual system, the histology and transcriptomic analyses were also focused on the optic nerve. We acknowledge that also investigating the spinal cord may have yielded additional information, but this would have been beyond the focus of this study.

Taken together, these observations suggest a beneficial effect of siponimod in the CNS by shifting microglia to a regenerative phenotype and protective effect on oligodendrocytes, in line with the proremyelination effects observed in the Xenopus laevis model.

In summary, siponimod demonstrated increased remyelination in the CC in the cuprizone demyelination model, proremyelination potential in the Xenopus model, and strong prophylactic and therapeutic effects in the mouse EAEON, as revealed by visual (functional and structural) readouts. Having used 3 experimental models in 2 different animal species strengthens our results in favor of a remyelinating potential for siponimod in MS.

**Acknowledgment**

France: The authors thank the ARSEP foundation, FRM (Fondation pour la Recherche Médicale), Bouvet-Labruyere Family, INSERM-DHOS, APHP (Assistance Publique des Hôpitaux de Paris), the program “Investissements d’Avenir” ANR-10-IAIHU-06, NeurATRIS, ANR grant BRECOMY to BZ, and NRJ foundation for their precious support related to basic and clinical research on remyelination in Paris. Novartis: the authors thank Claire Moeb, Catherine Aftasawo, Desrayaud Sandrine, Hager Claude, Neuhaus Anna, Lang Meike, Perrot Ludovic, Rudin Stefan, Wipfl Peter, and Zurbuegg Stefan for their key scientific and operational support. Germany: computational support of the Zentrum für Informations-und Medientechnologie, especially the HPC team (High Performance Computing) at the Heinrich Heine University, is acknowledged. The authors also thank Thorsten Wachtmeister for technical support and Zippora Kohne for technical assistance.

**Study Funding**

This work was supported by grants to PA from Novartis Pharma GmbH, the charitable Ilselore-Lückow Stiftung, and the charitable Dr.-Robert-Pfleger Stiftung. The study was partially funded by a research grant from Novartis to BZ and the European Union’s Horizon 2020 Research and Innovation Programme ENDpoiNTs project Grant Agreement number: 825759 and grant BRECOMY funded jointly by DFG and ANR to BZ.

**Disclosure**

M. Dietrich received speaker honoraria from Merck. M. Gliem has received honoraria for speaking/consultation from Bayer HealthCare and Boehringer Ingelheim and a research grant from B. Braun, outside the submitted work. B. Stankoff has received compensation for boards and/or lectures from Biogen, Sanofi Genzyme, Novartis, and Teva and research grants from Merck, Roche, and Sanofi Genzyme. C. Lubetzki has participated in advisory boards for Vertex, Roche, Biogen, Novartis, Genzyme,
and Merck and speaking honoraria from Ipsen and Biogen. P. Göttle performed consultancy work for GeNeuro and received support from the Research Commission of the medical faculty of the Heinrich Heine University. H.P. Hartung has received fees for serving on steering and data monitoring committees from Bayer HealthCare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva; his research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and by Almirall, Amicus Therapeutics Germany, Bayer HealthCare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva; his research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, and by Almirall, Amicus Therapeutics Germany, Bayer HealthCare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, and Teva. B. Zalc received research support from Novartis and Merck and travel grant from Merck. P. Albrecht received compensation for serving on scientific advisory boards for Ipsen, Novartis, and Biogen; he received speaker honoraria and travel support from Novartis, Teva, Biogen, Merz Pharmaceuticals, Ipsen, Allergan, Bayer HealthCare, Esa, UCB, and GlaxoSmithKline; he received research support from Novartis, Biogen, Teva, Merz Pharmaceuticals, Ipsen, and Roche. P. Ramseier, C. Beerli, S. Tisserand, N. Beckmann, D. Shimshek, and M. Bigaud are employees of the Novartis Institutes for BioMedical Research; the other authors report no disclosures. Go to Neurology.org/NN for full disclosures.

**Publication History**

Received by Neurology: Neuroimmunology & Neuroinflammation September 20, 2021. Accepted in final form January 27, 2022. Submitted and externally peer reviewed. The handling editor was Scott S. Zamvil, MD, PhD, FAAN.

### Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Michael Dietrich, PhD</strong></td>
<td>Department of Neurology, Heinrich Heine University, Dusseldorf, Medical Faculty, Dusseldorf, Germany</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Christina Hecker, MSc</td>
<td>Sorbonne Université, INSERM, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
<tr>
<td>Elodie Martin, PhD</td>
<td>Sorbonne Université, INSERM, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Dominique Langui, PhD</td>
<td>Sorbonne Université, INSERM, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
<tr>
<td>Michael Glem, MD</td>
<td>Department of Neurology, Heinrich Heine University, Dusseldorf, Medical Faculty, Dusseldorf, Germany</td>
<td>Analysis or interpretation of data</td>
</tr>
<tr>
<td>Bruno Stankoff, MD, PhD, PU-PH</td>
<td>Sorbonne Université, INSERM, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital; AP-HP, Saint-Antoine Hospital</td>
<td>Analysis or interpretation of data</td>
</tr>
<tr>
<td>Catherine Lubetzki, MD, PhD, PU-PH</td>
<td>Sorbonne Université, INSERM, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital; AP-HP, Pitié-Salpêtrière Hospital, Paris, France</td>
<td>Analysis or interpretation of data</td>
</tr>
<tr>
<td>Joel Gruchot, MSc</td>
<td>Department of Neurology, Heinrich Heine University, Dusseldorf, Medical Faculty, Dusseldorf, Germany</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
<tr>
<td>Peter Göttle, PhD</td>
<td>Department of Neurology, Heinrich Heine University, Dusseldorf, Medical Faculty, Dusseldorf, Germany</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
<tr>
<td>Andrea Issberner</td>
<td>Department of Neurology, Heinrich Heine University, Dusseldorf, Medical Faculty, Dusseldorf, Germany</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Milad Nasiri, MD</td>
<td>Department of Neurology, Heinrich Heine University, Dusseldorf, Medical Faculty, Dusseldorf, Germany</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Pamela Ramseier</td>
<td>Novartis Institutes for BioMedical Research, Basel, Switzerland</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Christian Beerli</td>
<td>Novartis Institutes for BioMedical Research, Basel, Switzerland</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Sarah Tisserand, MSc</td>
<td>Novartis Institutes for BioMedical Research, Basel, Switzerland</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
<tr>
<td>Nicolau Beckmann, PhD</td>
<td>Novartis Institutes for BioMedical Research, Basel, Switzerland</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and analysis or interpretation of data</td>
</tr>
<tr>
<td>Derya Shimshek, PhD</td>
<td>Novartis Institutes for BioMedical Research, Basel, Switzerland</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
</tbody>
</table>

Continued
Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Petzsch, PhD</td>
<td>Biological and Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Medical Faculty</td>
<td>Major role in the acquisition of data and analysis or interpretation of data</td>
</tr>
<tr>
<td>David Akbar, MSc</td>
<td>Sorbonne Université, Inserm, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Bodo Levkau, Prof.</td>
<td>Institute for Molecular Medicine III, University Hospital Düsseldorf and Heinrich Heine University Düsseldorf</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Holger Stark, Prof.</td>
<td>Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Karl Köhrer, Prof.</td>
<td>Biological and Medical Research Center (BMFZ), Heinrich Heine University Düsseldorf, Medical Faculty</td>
<td>Analysis or interpretation of data</td>
</tr>
<tr>
<td>Hans-Peter Hartung, Prof.</td>
<td>Department of Neurology, Heinrich Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany; Brain and Mind Center, University of Sydney, NSW, Australia; Medical University of Vienna, Vienna, Austria</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Patrick Kury, Prof.</td>
<td>Department of Neurology, Heinrich Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Sven Günther Meuth, Prof.</td>
<td>Department of Neurology, Heinrich Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Marc Bigaud, PhD</td>
<td>Novartis Institutes for BioMedical Research, Basel, Switzerland</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Bernard Zalc, Prof.</td>
<td>Sorbonne Université, Inserm, CNRS, Institut du Cerveau, Pitié-Salpêtrière Hospital</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
<tr>
<td>Philipp Albrecht, Prof.</td>
<td>Heinrich Heine University Düsseldorf, Medical Faculty, Düsseldorf, Germany</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and analysis or interpretation of data</td>
</tr>
</tbody>
</table>

References


Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
Michael Dietrich, Christina Hecker, Elodie Martin, et al.
*Neurol Neuroimmunol Neuroinflamm* 2022;9;
DOI 10.1212/NXI.0000000000001161

This information is current as of March 30, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/9/3/e1161.full.html

References
This article cites 42 articles, 5 of which you can access for free at:
http://nn.neurology.org/content/9/3/e1161.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis
Optic neuritis; see Neuro-ophthalmology/Optic Nerve
http://nn.neurology.org/cgi/collection/optic_neuritis

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

*Neurol Neuroimmunol Neuroinflamm* is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.